Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Health Estate|March 24, 2011
Maintaining control is team's vital roleLiz Haywood, Chris Frankel, Andrew Johns, et al.
Expert Opinion on Pharmacotherapy|February 21, 2019
The pharmacologic management of multiple myeloma in older adultsJessica L Dempsey, Andrew Johns, Ashley E Rosko, et al.
Cancer Investigation|August 2, 2017
Primary Management of Squamous Cell Carcinoma of the Anal Canal: A 30-year Community Hospital ExperienceMohit S Agarwal, Daniel A Jones, Charles M Mendenhall, et al.
American Journal of Clinical Oncology|June 28, 2017
Radiotherapy Alone or With Chemotherapy in the Management of Carcinoma of the Supraglottic Larynx: A 25-Year Community Hospital ExperienceAmy R Rao, Daniel A Jones, Charles M Mendenhall, et al.
Cancer Immunology, Immunotherapy : CII|February 24, 2021
Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse eventsAndrew Nashed, Shijun Zhang, Chien-Wei Chiang, et al.
Cancer Immunology, Immunotherapy : CII|July 31, 2020
Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancerMingjia Li, Daniel Spakowicz, Songzhu Zhao, et al.
Cancer Immunology, Immunotherapy : CII|October 7, 2021
Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survivalTyler C Haddad, Songzhu Zhao, Mingjia Li, et al.
Journal of Cancer Research and Clinical Oncology|September 7, 2022
Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survivalAbdul Miah, Gabriel Tinoco, Songzhu Zhao, et al.
Cancer Investigation|October 10, 2025
Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint InhibitorsSandip H Patel, Songzhu Zhao, Mingjia Li, et al.
Future Oncology (London, England)|October 30, 2025
Phase 2 study of dostarlimab plus niraparib in stage III-IV recurrent or refractory Penile squamous cell carcinomaFiras Hatoum, Gabriel Roman Souza, Jeff Johnson, et al.
Pageof 2